24,800
-20.00%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Seegene
Its shares trade on KOSDAQ under the ticker 096530.KQ. It has been listed since 10 September 2010. In the fiscal year to 31 December 2025, it reported revenue of ₩474.23bn and net income of ₩48.27bn. At that date it held total assets of ₩1.24trn and shareholders' equity of ₩1.02trn.
Seegene, Inc. engages in the manufacturing and distributing of molecular diagnostics and reagents. The company is headquartered in Seoul, Seoul. The company went IPO on 2010-09-10. The firm mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The firm provides its products under the brand names of Seeplex, Anyplex and Magicplex. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Sept 2010
- Website
- seegene.com ↗
Leadership
Pay as last reported
- Mr. Dae Hun LeeCo-President, Co-Chief Executive Officer, Director
- Mr. Jin Su ChoiCo-President, Director, since 2024₩516.0m
- Mr. Jong Yun CheonCo-Chief Executive Officer, Director, since 2024₩1.54bn
- Mr. Beom Jun KimVice President₩765.0m
- Mr. Jun Beom KimVice President₩659.0m
- Mr. Gi Seon LeeVice President₩809.0m
- Mr. Dae Ho ShinVice President
- Mr. Sang Heon ShinVice President
- Mr. Bu Hyeon YangVice President
- Mr. Dae Hyeok AhnManaging Director
- Ms. Eun Sin BaeManaging Director
- Mr. Eun Cheol ChoManaging Director, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 41
- Social
- 99
- Governance
- 22
- Direct emissions (scope 1)
- 0 t
- Energy emissions (scope 2)
- 6,845 t
- Women in the workforce
- 42.21219%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Seegene Inc. provides Seeplex for infectious pathogens inspection in South Korea.
- Seegene Inc. offers Anyplex for drug resistance inspection globally.
- Seegene Inc. distributes Magicplex for somatic mutation cancer inspection internationally.
Weaknesses
- Seegene Inc. focuses on molecular diagnostics without expanding into other Health Care segments.
- Seegene Inc. relies on Seoul headquarters for operations without international offices.
- Seegene Inc. has limited product range in the Biotechnology sector.
Opportunities
- Seegene Inc. can expand into HPV inspection products in the United States market.
- Seegene Inc. can grow in the European Union market for SNP inspection products.
- Seegene Inc. can increase sales of real-time detection instruments in Asia Pacific.
Threats
- Seegene Inc. faces competition from other Biotechnology firms in South Korea.
- Seegene Inc. encounters regulatory challenges in the European Union for diagnostic products.
- Seegene Inc. experiences supply chain disruptions in the Asia Pacific region.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.